Teikoku Seiyaku has been and will continue to be a Global Specialty Pharmaceutical Company.

Teikoku Seiyaku’s Lidoderm®, the analgesic hydrogel patch for the treatment of post-herpetic neuralgia, was the first prescription hydrogel patch in the U.S. It was launched globally by Teikoku Seiyaku and is still highly regarded throughout the U.S. as an authorized generic. It is also used by many patients in more than 50 countries around the world, including Europe and South America.
Based on our expertise, track record, and reliability in the field of external products, especially patch formulations, we will continue our research and development to relieve various kinds of pain for people around the world.
In addition, through our recognition as a global specialty pharmaceutical company in the field of patch formulations, we will continue to strengthen our collaboration with overseas pharmaceutical companies. Collaborations with global partners is especially important given the lag time in drug approval in Japan.